---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-047871"
form_type: "8-K"
ticker: "ANVS"
cik: "0001477845"
company_name: "Annovis Bio, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T14:51:25.984169+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Annovis Bio starts Phase 3 Alzheimer's trial, reports Q1 net loss $0.32 per share, cash $22.2M

## Summary
- First participants entered pivotal Phase 3 AD trial on Feb 5, 2025; planning 760 participants, evaluating buntanetap.
- Cash and equivalents $22.2M as of Mar 31, 2025 (vs $10.6M a year ago).
- R&D expenses $5.0M in Q1 2025 vs $6.5M Q1 2024; G&A flat at $1.3M.
- Net loss per share $0.32 basic/diluted for Q1 2025 vs $0.10 basic and $0.72 diluted in Q1 2024.
- Appointed Andrew Walsh (VP Finance) as Principal Financial Officer; salary $264,000 + 25% target bonus.

## SEC filing metadata
- accession: 0001104659-25-047871
- form_type: 8-K
- ticker: ANVS
- cik: 0001477845
- company_name: Annovis Bio, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1477845/000110465925047871/0001104659-25-047871-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1477845/000110465925047871/tm2514854d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-047871
- JSON: https://secwatch.observer/filing/0001104659-25-047871.json
- Plain text: https://secwatch.observer/filing/0001104659-25-047871.txt

## Key facts
- Executive change
  Andrew Walsh was appointed as Principal Financial Officer at Annovis Bio, Inc..
  - Action: appointed
  - Role: Principal Financial Officer
  source text: On May 9, 2025, the Board of Directors appointed Andrew Walsh, the Company’s current Vice President of Finance, as the Company’s Principal Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1477845/000110465925047871/0001104659-25-047871-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.